Testing a new drug for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called MDX2004 for people with advanced solid tumors (cancer that has spread or can't be removed). The goal is to see if the drug is safe and if it helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your cancer must be advanced (has spread or cannot be removed with surgery).
- You should be able to do daily activities without help (ECOG 0 or 1).
- You need at least one tumor that can be measured on a scan (like CT or MRI).
- Your heart, blood, liver, and kidneys must be working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
This trial tests a new drug called DXC018 for people with advanced solid tumors that have not responded to standard treatments or for whom no standard treatment exists. The goal is to see if the drug can shrink or slow the growth of these tumors.
This trial tests a new drug called ADRX-0405 in people with advanced solid tumors like prostate, stomach, or lung cancer. The goal is to see how safe it is and if it shrinks tumors.
This trial tests a new drug called HDM2006 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
This trial tests DXC014, a new drug, in people with advanced solid tumors, including prostate cancer. It aims to see if the drug is safe and effective.
This trial is testing whether a new drug called CT7439 can help people with advanced solid tumors that have not responded to other treatments. It is a phase 1/2 study that also checks the drug's safety and how well it works.
Hear when a new Advanced Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.